Equity Profile

TXG

10x Genomics, Inc.

Health CareLife Sciences Tools & Services$7.6B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

10x Genomics, Inc. is a health care company focused on life sciences tools and services, particularly in genomic analysis....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TXG Q2-2026 Earnings Preview

Context

Company Snapshot

10x Genomics, Inc. is a health care company focused on life sciences tools and services, particularly in genomic analysis. With a market cap of $8 billion, it plays a crucial role in advancing scientific research and personalized medicine through innovative technologies.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+43.83%

Avg Stock Reaction

+0.03%

Last Quarter Recap

In Q1-2026, 10x Genomics reported an EPS of -$0.10, outperforming estimates by nearly 66%. However, revenue details were not disclosed, and the stock saw a slight decline the following day.

Management Promises & Guidance

Continued focus on innovation in genomic technologies.
Commitment to expanding market reach and customer base.
Plans to enhance product offerings and improve operational efficiency.

Expectations

Wall Street Expectations

Overall, expectations for the upcoming earnings report are mixed, with some investors hopeful for continued EPS surprises while others remain cautious due to lack of revenue guidance.

Bull Case

The optimistic view hinges on the company's ability to maintain its strong EPS surprise track record, potentially leading to a positive market reaction.

Bear Case

Conversely, a lack of revenue growth or negative commentary could lead to a decline in stock price, especially given the high implied volatility in the options market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported revenue for Q2-2026?

Revenue figures are crucial for assessing the company's growth trajectory and market demand for its products.

How will management address the current competitive landscape in genomic technologies?

Understanding management's perspective on competition can provide insights into the company's strategic direction and potential challenges.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for 10x Genomics to leverage new product innovations that could drive significant revenue growth.

Supporting Evidence

The company has a strong history of beating EPS estimates, which may not be fully reflected in current market expectations.

Options pricing suggests heightened volatility, indicating that traders expect a larger reaction than historical averages.

Recent trends in genomic research suggest increasing demand for advanced genomic tools, which could benefit 10x Genomics.

Key Risk

If the company reports revenue growth significantly above current expectations, it could challenge the cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to sustain growth in a competitive market while managing costs effectively.

Bull Confirmed If

A revenue growth rate exceeding 15% year-over-year would confirm the bull case.

Bear Confirmed If

If EPS falls below -$0.20, it would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±30.9%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±30.9% while TXG has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

69.6%

Calls (444K)P/C Ratio: 0.03Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If 10x Genomics beats expectations and raises guidance, history suggests a potential average move of +3.2% on the stock.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may experience muted movement.

Miss

A miss on EPS could lead to a decline, with historical patterns suggesting an average drop of around +1.52%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on new product launches and their expected impact on revenue.
2Management's outlook on market trends in genomic technologies.
3Updates on customer acquisition and retention strategies.
4Any commentary on cost management and operational efficiency.
5Insights into competitive positioning and market share.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

10x Genomics, Inc. is a health care company focused on life sciences tools and services, particularly in genomic analysis....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TXG Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+43.83%

Avg Stock Reaction

+0.03%

Last Quarter Recap

In Q1-2026, 10x Genomics reported an EPS of -$0.10, outperforming estimates by nearly 66%. However, revenue details were not disclosed, and the stock saw a slight decline the following day.

Management Promises & Guidance

Continued focus on innovation in genomic technologies.
Commitment to expanding market reach and customer base.
Plans to enhance product offerings and improve operational efficiency.

Expectations

Wall Street Expectations

Overall, expectations for the upcoming earnings report are mixed, with some investors hopeful for continued EPS surprises while others remain cautious due to lack of revenue guidance.

Bull Case

The optimistic view hinges on the company's ability to maintain its strong EPS surprise track record, potentially leading to a positive market reaction.

Bear Case

Conversely, a lack of revenue growth or negative commentary could lead to a decline in stock price, especially given the high implied volatility in the options market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported revenue for Q2-2026?

Revenue figures are crucial for assessing the company's growth trajectory and market demand for its products.

How will management address the current competitive landscape in genomic technologies?

Understanding management's perspective on competition can provide insights into the company's strategic direction and potential challenges.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for 10x Genomics to leverage new product innovations that could drive significant revenue growth.

Supporting Evidence

The company has a strong history of beating EPS estimates, which may not be fully reflected in current market expectations.

Options pricing suggests heightened volatility, indicating that traders expect a larger reaction than historical averages.

Recent trends in genomic research suggest increasing demand for advanced genomic tools, which could benefit 10x Genomics.

Key Risk

If the company reports revenue growth significantly above current expectations, it could challenge the cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to sustain growth in a competitive market while managing costs effectively.

Bull Confirmed If

A revenue growth rate exceeding 15% year-over-year would confirm the bull case.

Bear Confirmed If

If EPS falls below -$0.20, it would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±30.9%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±30.9% while TXG has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

69.6%

Calls (444K)P/C Ratio: 0.03Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If 10x Genomics beats expectations and raises guidance, history suggests a potential average move of +3.2% on the stock.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may experience muted movement.

Miss

A miss on EPS could lead to a decline, with historical patterns suggesting an average drop of around +1.52%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on new product launches and their expected impact on revenue.
2Management's outlook on market trends in genomic technologies.
3Updates on customer acquisition and retention strategies.
4Any commentary on cost management and operational efficiency.
5Insights into competitive positioning and market share.